Product Description
LSR-1019 is Lusaris lead program,it is a proprietary sublingual formulation of 5-MeO-DMT. LSR-1019 is a best-in-class psychedelic therapeutic in development for treatment-resistant depression and additional neuropsychiatric indications. (Sourced from: https://lusaristx.com/)
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lusaris
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Depressive Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|